• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Bayer Leverages ConcertAI’s Translational360™ Platform for AI-Driven Oncology

by Syed Hamza Sohail 04/25/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI’s Translational360™ and AI SaaS solutions, which use artificial intelligence and machine learning (AI/ML)-derived insights to accelerate clinical development in precision oncology.

– The agreement will fully leverage ConcertAI’s newly launched Translational360™, an integrated research-grade longitudinal clinical molecular database that taps into the CancerLinQ network of de-identified cancer patient data from over 9 million records coming from all 50 states in the U.S.

ConcertAI Advances Oncology R&D Through Integrated AI and Multi-Modal Data Solutions

ConcertAI is a leading provider of predictive and generative AI SaaS solutions, offering real-world data research tools tailored for healthcare and life sciences. Headquartered in Cambridge, MA, the company operates globally with offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. Its mission is to accelerate clinical insights and patient outcomes through research-ready data, proprietary CARAai™ technologies, and scientific expertise. In partnership with over 46 top biomedical innovators, 2,000 healthcare providers, and numerous medical societies, ConcertAI delivers scalable, impactful research and AI-driven solutions across the healthcare ecosystem.

Core platforms include:

  • TeraRecon®, which offers advanced radiological image visualization and clinical AI decision support for MRI and CT imaging.
  • CancerLinQ®, an ASCO-aligned initiative that provides oncology practices with automated QOPI and ASCO Certified® quality solutions, alongside SmartLinQ™ analytics services to enhance care quality and performance metrics.

A central innovation, Translational360™, integrates clinical, genomic, transcriptomic, and whole-slide imaging (WSI) data derived from comprehensive molecular testing. This platform supports deeper phenotypical and genomic characterization, advancing translational research by enabling researchers to:

  • Uncover disease-specific molecular mechanisms
  • Understand patient-specific treatment responses
  • Explore inter-patient variability crucial to novel therapeutic development

Transcriptomics, a key component of Translational360™, is increasingly central to biopharma research. It enables investigators to resolve ambiguities in early-phase clinical trial outcomes by identifying both idiosyncratic positive and negative responses. Through the use of multi-modal, multi-genomic, and transcriptomic data, combined with AI-based analytics, ConcertAI supports:

  • The prioritization of therapeutic programs with the highest probability of success
  • The design of precision-informed clinical trials

According to Dr. Jeff Elton, CEO of ConcertAI, “This partnership advances causal biological inferences by integrating multi-modal and multi-molecular data with AI/ML-based approaches across the discovery-to-development continuum. It accelerates oncology pipelines and enables biopharma partners to deliver better medicines faster.” He emphasized that the collaboration builds on a longstanding relationship and is distinctive in its use of both tissue and liquid biopsy molecular data. This approach enables:

  • AI modeling of treatment response patterns and resistance mechanisms
  • Data-driven prioritization of clinical programs
  • Optimization of study design based on predicted therapeutic benefit and success rates

Together, these capabilities position ConcertAI and its partners at the forefront of translational oncology innovation.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

The AI Paradox in Healthcare: Notable CEO Shares Why Moving Too Slowly is a Greater Risk

Most-Read

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Patient Square Capital Acquires Premier in $2.6B Deal

Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market

Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market

CVS Health Subsidiary Omnicare Files for Bankruptcy to Tackle Financial Challenges

CVS Health Subsidiary Omnicare Files for Bankruptcy to Tackle Financial Challenges

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |